The study by Gupta and colleagues (1) demonstrates the utility of multiparametric MRI (mpMRI) for evaluating early response and acquired resistance to KRAS G12D inhibition in pancreatic cancer models.Although the findings are compelling, this work also highlights critical opportunities to advance MRI-based biomarkers for clinical translation in KRAS-driven malignancies.The authors elegantly link early apparent diffusion coefficient (ADC) increases to KRASi-induced apoptosis and reduced cellularity, corroborated by histopathology.This aligns with prior studies showing that ADC changes predict treatment response in gastrointestinal cancers (2).Notably, the inverse correlation between Ktrans and microvascular density reveals stromal reprogramming dynamics previously undetectable by size-based metrics, echoing findings from antiangiogenic therapy trials (3).The reversal of MRI biomarkers at resistance stages provides novel insights into adaptive mechanisms that could guide combination therapies.Three key implications merit emphasis